TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000381577
  • Gene Name:PD-L1
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:immune checkpoint pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB08896
  • Drug Name:Regorafenib
  • Drug Method:down-regulated the gene expression the gene expression

Disease basic infommation

  • Disease:hepatocellular carcinoma
  • Tissue:patients tissues

Other information

  • Title:Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells
  • Journal:Clin Chim Acta
  • Published:2018
  • PubMed ID:29940148
  • Abstract:Background:The molecular mechanisms involved in the development and metastasis of hepatocellular carcinoma (HCC) are complex. Molecule-targeted drugs are characterized by strong specificity and low toxicity, but the clinical research of these drugs still exhibits many difficulties, such as poor target specificity. With the in-depth study of the tumor immunological theory, therapies based on overcoming the tumor immune escape to produce a specific effective tumor immune response has gradually become a hot topic in tumor research. We hope that by studying the effects of liver-targeted drugs on the expression of immune-related proteins in hepatocellular carcinoma cells, we will find a potential link to further guide the clinical drug use. Methods:Human hepatoma Hep3B cells were used to establish liver cancer xenografts by inoculating 40 BALB/c nude mice. The following five groups of mice (8 mice per group) were randomly set up: lenvatinib group, apatinib group, sorafenib group, regorafenib group, and dimethyl sulfoxide (DMSO) group. After treatment, we analyzed PD-L1 and B7-H3 mRNA using the real-time polymerase chain reaction (PCR) assay and assessed the PD-L1 and B7-H3 protein expression by Western immunoblotting. Results:Real-time PCR results suggested that the mRNA expression of PD-L1 in the lenvatinib group was significantly higher than that in the control group, while its expression in the regorafenib group was significantly lower than that in the control group (both p < .05). Western immunoblotting results suggested that, compared with the control group, PD-L1 protein was increased in the lenvatinib group, while its expression in the regorafenib group was decreased. Conclusion:Lenvatinib and regorafenib affected the expression of PD-L1 in the process of anti-HCC.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3